Thermo Fisher Scientific
Global maker of lab instruments, reagents, and clinical trial support services.
The call
Thermo Fisher keeps expanding through regulated diagnostics and consumable lock-in, with AI reinforcing rather than replacing its business.
Thermo Fisher Scientific sells machines, chemicals, and testing services that drug makers and research labs rely on every day. It is hard to replace because customers have spent years building their work around Thermo Fisher's products, hospitals and regulators approve Thermo Fisher's diagnostic tests, and the company owns the supply chain for the materials scientists need to reorder. Competitors like Danaher and Agilent make similar tools but have not pushed Thermo Fisher out of its main business. The big question is whether new artificial intelligence partnerships will actually make money and whether demand from biotech and pharma companies stays strong over the next two years.
Why
01
AI pressure: None apparent. AI partners like NVIDIA and OpenAI extend its lab tools rather than replace its instruments or regulated services. Could AI do the core job? Unlikely.
02
Bigger players: Danaher. Danaher, Agilent, and Bruker compete in niches but haven't displaced its core instrument and consumables business. Could a giant copy it? No, they are blocked.
03
What protects it. FDA clearances, an installed instrument base tied to proprietary consumables, and owned global distribution keep customers locked in.
What would change this call
Q2 2026 earnings (July 23, 2026) organic growth and instrument demand trends. Shows whether biotech/pharma capex spending is sustaining Thermo Fisher's core sales.
Regulatory or legal action tied to the antibody catalog-image manipulation finding. Would show whether the controversy escalates into diagnostic product liability or reputational damage.
Clario CRO segment margin and growth data through 2027 earn-out milestones. Shows whether the Clario acquisition is integrating well or dragging on CRO performance.
Regulatory or legal action tied to the antibody catalog-image manipulation finding. Would show whether the controversy escalates into diagnostic product liability or reputational damage.
Clario CRO segment margin and growth data through 2027 earn-out milestones. Shows whether the Clario acquisition is integrating well or dragging on CRO performance.
Key numbers
- FY2025 revenue $44.56B, up 4% YoY
- Q1 2026 revenue $11.01B, up 6.2% YoY
- Market cap about $198B
Named risks
- Antibody catalog image manipulation finding (May 2026) creates unresolved regulatory and reputational exposure.
- Section 301 China tariff exposure upheld by Supreme Court on June 15, 2026, pressures instrument manufacturing costs.
- Clario integration and $400M earn-out milestones through 2027 could strain CRO segment margins if execution falters.
- Microbiology divestiture expected to dilute adjusted EPS by $0.15 in year one after H2 2026 close.
- Leadership churn with COO and CFO transitions in March 2026 during major M&A integration period.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Bruker Corporation | contesting | Directly rivals Thermo's Orbitrap mass spec line in the mass spectrometry niche, as of mid-2026 |
| Danaher Corporation | contesting | Competes across life-sciences tools but has not displaced Thermo's core instrument-to-CRO position as of 2026 |
| Agilent Technologies | contesting | Rivals in analytical instruments; Thermo remains largest of the big three tools conglomerates by revenue in 2026 |
Questions people ask
- Is Thermo Fisher Scientific profitable in 2026?
- Yes. Thermo Fisher reported FY2025 GAAP net income of $6.70 billion on revenue of $44.56 billion as of December 31, 2025, and Q1 2026 revenue rose 6.2% YoY to $11.01 billion with EPS of $5.44, per its January 29, 2026 earnings release.
- Could AI replace Thermo Fisher Scientific's business?
- Unlikely soon. Thermo Fisher's moat rests on FDA-cleared diagnostics, proprietary instrument hardware, and regulated CRO/CDMO infrastructure (PPD, Patheon, Clario). Its AI partnerships with NVIDIA (announced January 12, 2026) and OpenAI (October 16, 2025) layer automation onto instruments rather than replacing regulated hardware or clinical trial services.
- Who is Thermo Fisher Scientific's biggest competitor?
- Danaher Corporation and Agilent Technologies are its closest full-line peers, while Bruker Corporation directly contests the mass spectrometry niche against Thermo's Orbitrap line. As of 2026, Thermo Fisher remains the largest of the big three life-sciences-tools conglomerates by revenue.
- Is Thermo Fisher Scientific laying off employees in 2026?
- No broad layoffs are reported. Company-disclosed headcount was 125,000 as of December 31, 2025, unchanged from December 31, 2024, though down from 130,000 in 2022. The company had 2,836 open roles tracked as of July 2026, concentrated in the US, India, and UK.
- Who owns Thermo Fisher Scientific?
- Thermo Fisher Scientific is a publicly traded company (NYSE: TMO) with no controlling parent, valued at roughly $198 billion in market cap as of July 20, 2026. It is itself a serial acquirer, having completed an $8.875 billion purchase of Clario Holdings in March 2026.
- What is Thermo Fisher Scientific's revenue guidance for 2026?
- Thermo Fisher guided FY2026 revenue of $47.3 billion to $48.1 billion with EPS of $24.64 to $25.12, issued alongside its January 29, 2026 fourth-quarter and full-year 2025 earnings report.
Timeline
- 2026-06-15US Supreme Court denied challenge, leaving Section 301 China tariff exposure in place
- 2026-05Finding reported that many antibody catalog images were manipulated to falsely show efficacy
- 2026-04-27Agreed to sell microbiology business (~$645M revenue) to Astorg for ~$1.075B
- 2026-03-31COO Michel Lagarde departed; Gianluca Pettiti named President and COO, James Meyer named CFO
- 2026-03-24Completed $8.875B acquisition of Clario Holdings for clinical trial endpoint data
- 2026-01-29Reported FY2025 revenue of $44.56B, net income $6.70B; issued FY2026 guidance
- 2026-01-12Announced strategic AI collaboration with NVIDIA for autonomous lab infrastructure
- 2025-10-16Announced collaboration with OpenAI to embed AI in clinical research workflows
Head to head
Revision history
20 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results (2026-01-29)
- Thermo Fisher Scientific (TMO) to Announce Quarterly Earnings on Thursday (2026-07-16)
- Thermo Fisher Scientific (TMO) Earnings Date and Reports 2026 (2026-07-15)
- Thermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc. (2026-03-24)
- Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg (2026-04-27)
- Thermo Fisher Scientific Announces Strategic Collaboration With NVIDIA (2026-01-12)
- Thermo Fisher's growing AI ecosystem aims to transform how science is done
- Thermo Fisher Scientific (TMO) Number of Employees 1994-2025 (2026-07-09)
- gurufocus.com (2026-07-20)
- Thermo Fisher Scientific Inc. Organizational Structure (2026-03-31)
- Section 301 China Tariff Litigation Update (2026-06-16)
- Exploring Analyst Estimates for Thermo Fisher (TMO) Q2 Earnings (2026-07-20)